Blood Glucose Control Using African Traditional Fermented Foods (ATFF)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05960019 |
Recruitment Status :
Recruiting
First Posted : July 25, 2023
Last Update Posted : January 30, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
PreDiabetes | Dietary Supplement: Fermented milk product Dietary Supplement: Fermented cereal based product Behavioral: Behavioural modification counselling | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 252 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Study of the Hypoglycemic Effect of African Traditional Fermented Foods Amongst Pre-diabetic Adults. |
Actual Study Start Date : | January 17, 2024 |
Estimated Primary Completion Date : | November 30, 2024 |
Estimated Study Completion Date : | December 17, 2024 |
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
Arm | Intervention/treatment |
---|---|
Experimental: Fermented milk product
Dietary supplement (Maziwa Mala) This is a type of cultured dairy milk, that is prepared through mesophilic fermentation of milk that is widely available in Kenya. Participants will be expected to consume 250ml of the mala each day for breakfast.
|
Dietary Supplement: Fermented milk product
This is a type of cultured bovine milk, that is prepared through mesophilic fermentation of milk, that is widely available in Kenya. Participants will be expected to consume 250ml of the mala each day for breakfast.
Other Name: Maziwa mala |
Experimental: Fermented cereal based porridge
Dietary supplement (Uji) This is a fermented cereal-based porridge prepared from a mix of ground millet and sorghum that is mixed with water into a gruel which is fermented into a non-alcoholic beverage or meal depending on desired thickness. Participants will be expected to consume 250ml of the porridge each day for breakfast.
|
Dietary Supplement: Fermented cereal based product
This is a fermented cereal-based porridge prepared from a mix of ground millet and sorghum that is mixed with water into a gruel which is fermented into a non-alcoholic beverage or meal depending on desired thickness. Participants will be expected to consume 250ml of the porridge each day for breakfast.
Other Name: Uji |
Active Comparator: Standard of Care
Standard of care shall comprise behavioural (lifestyle) modification counselling delivered monthly. This shall consist of provision of counselling on lifestyle modification in an effort to help the participants prevent progression of the pre-diabetes and provide help with any emerging complications of the disease. Counselling on lifestyle modification shall comprise provision of standard dietary and exercise advice for pre-diabetics by a study doctor.
|
Behavioral: Behavioural modification counselling
Standard of care shall comprise behavioural (lifestyle) modification counselling delivered monthly. This shall consist of provision of counselling on lifestyle modification in an effort to help the patients prevent progression of the pre-diabetes and provide help with any emerging complications of the disease. Counselling on lifestyle modification shall comprise provision of standard dietary and exercise advice for pre-diabetics by a study doctor.
Other Name: Lifestyle modification counselling |
- Change in HbA1c [ Time Frame: "12 weeks" ]Change in levels of glycated haemoglobin
- Change in lipid profile [ Time Frame: "4 weeks" and "12 weeks" ]Change in levels of total cholesterol, triglycerides, HDL, LDL
- Change in weight [ Time Frame: "4 weeks" and "12 weeks" ]Change in weight
- Change in CRP levels [ Time Frame: "4 weeks" and "12 weeks" ]Change in levels of inflammatory marker C reactive protein
- Change in waist circumference [ Time Frame: "4 weeks" and "12 weeks" ]Change in waist circumference
- Change in FBG [ Time Frame: "4 weeks" and "12 weeks" ]Change in levels of fasting blood glucose
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: "from date of randomization through to study completion, an average of 12 weeks" ]Adverse events occurring due to consumption of allocated fermented food
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Clinically diagnosed pre-diabetes (diagnosed less than 6 months ago), defined as HbA1c between 5.7% and 6.4%,
- Both male and female prediabetic individuals
- Aged between 18 and 65 years
- Seeking clinic services at the selected AKU-outreach facilities for at least 3 visits (including seeking services for separate reasons other than pre-diabetes for the purpose of determining affiliation)
Exclusion Criteria:
-
Currently on any of the following:
- glucose lowering medication (including insulin therapy)
- steroid therapy,
- immunosuppressive therapy,
- medication for gastric disease,
- warfarin or other coumarin derivates,
- Vitamin C or E, Iron or B12
- erythropoietin
- antiretrovirals
- ribavirin
- dapsone
- Chronic use (defined as consumption of more than 3 months) of non-steroidal anti-inflammatory drugs or aspirin
- Individuals that have consumed antibiotics in the last month.
- Individuals that regularly consume fermented foods or took nutritional supplements including probiotics during the 3 months prior to screening. Regular consumption shall be defined as consuming at least 250ml of fermented foods on six days in a week.
- Individuals who at the time of enrolment are smokers, regularly consume alcohol (defined as having had at least 12 drinks in the past year but 3 drinks or fewer per week, on average over the past year) or are suffering from drug addiction including chronic opiate use.
- Individuals with a history of gastrointestinal surgery (gastrectomy, bariatric surgery, or colostomy), splenectomy or gastrointestinal malignancy.
-
Individuals known to be:
- HIV+ve,
- suffering from blood disorders such as Reticulocytosis or any form of Anaemia (including Iron deficiency, B12 Deficiency) or Haemoglobinopathies.
- Pregnant or lactating,
- with serious organic or metabolic conditions [such as malignant disease, pancreatitis, endocarditis, liver, or severe kidney disease (serum creatinine level above the normal range or macroalbuminuria including chronic renal failure), severe pulmonary or heart disease], splenomegaly, rheumatoid arthritis, hypertriglyceridemia, in a terminal stage of illness, or experiencing acute or severe episodes of mental illness at the time of enrolment.
- Individuals with allergies to dairy or cereal products such as millet.
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05960019
Contact: Rosebella A Iseme-Ondiek, PhD | +254706267212 ext +254709931506 | rosebella.ondiek@aku.edu; rosebellaiseme@gmail.com |
Kenya | |
Aga Khan Outreach Facilities | Recruiting |
Kiambu, Kenya | |
Aga Khan Outreach Facilities | Recruiting |
Nairobi, Kenya |
Principal Investigator: | Rosebella A Iseme-Ondiek, PhD | Aga Khan University |
Responsible Party: | Rosebella Iseme-Ondiek, Assistant Professor, Aga Khan University |
ClinicalTrials.gov Identifier: | NCT05960019 |
Other Study ID Numbers: |
2022-104 |
First Posted: | July 25, 2023 Key Record Dates |
Last Update Posted: | January 30, 2024 |
Last Verified: | January 2024 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Prediabetic State Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |